LAVA Therapeutics Up 7% After Orphan Drug Designation
14 October 2021 - 05:51AM
Dow Jones News
By Josh Beckerman
LAVA Therapeutics NV shares were up 7% to $7.70 Wednesday after
a potential treatment of chronic lymphocytic leukemia received an
orphan drug designation from the U.S. Food and Drug
Administration.
The FDA lists the generic name of the potential treatment as
immunoglobulin VHH fragment-linker-VHH fragment, anti-CD1d and
anti-[Vdelta2 T-cell receptor], humanized monoclonal antibody.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
October 13, 2021 14:36 ET (18:36 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From Jul 2022 to Aug 2022
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From Aug 2021 to Aug 2022